Use of viral vectors to create animal models for Parkinson's disease

Neurobiology of Disease

Volumn 48, Issue 2, 2012, Pages 189-201

  Löw, Karin ^a   Aebischer, Patrick ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; DOPAMINE; LENTIVIRUS VECTOR; LEUCINE RICH REPEAT KINASE 2; PARKIN; PARVOVIRUS VECTOR; PROTEIN; PROTEIN CDCREL 1; PROTEIN JTV; PROTEIN PAEL R; SHORT HAIRPIN RNA; SYNAPTOPHYSIN; SYNPHILIN 1; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ALPHA SYNUCLEIN GENE; AUTOSOMAL DOMINANT INHERITANCE; CALLITRICHINAE; DJ 1 GENE; DOPAMINERGIC NERVE CELL; GENE; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; LRRK 2 GENE; NERVE CELL DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKIN GENE; PARKINSON DISEASE; PHENOTYPE; PINK 1 GENE; PRIMATE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; RODENT; SUBSTANTIA NIGRA; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS STRAIN;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NERVE TISSUE PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, G-PROTEIN-COUPLED; SEPTINS; UBIQUITIN-PROTEIN LIGASES; VIRUSES;

EID: 84865535547     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.038     Document Type: Review

References (107)

1. Azeredo da Silveira S., et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum. Mol. Genet. 2009, 18:872-887.
2. Beites C.L., et al. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat. Neurosci. 1999, 2:434-439.
3. Biskup S., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006, 60:557-569.
4. Bonifati V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
5. Chartier-Harlin M.C., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
6. Choi P., et al. SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res. 2003, 117:179-189.
7. Chung K.K., et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med. 2001, 7:1144-1150.
8. Chung K.K., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004, 304:1328-1331.
9. Cookson M.R., et al. Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol. 2008, 1:217-231.
10. Dawson T.M., et al. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
11. Deglon N., et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum Gene Ther. 2000, 11:179-190.
12. Di Fonzo A., et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005, 365:412-415.
13. Dong Z., et al. Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12438-12443.
14. Dusonchet J., et al. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Neurobiol. Dis. 2009, 35:32-41.
15. Dusonchet J., et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J. Neurosci. 2011, 31:907-912.
16. Engelender S., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 1999, 22:110-114.
17. Eslamboli A., et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130:799-815.
18. Galvin J.E., et al. Synucleinopathies: clinical and pathological implications. Arch. Neurol. 2001, 58:186-190.
19. Giasson B.I., et al. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 2006, 59:315-322.
20. Gilks W.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
21. Gloeckner C.J., et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 2006, 15:223-232.
22. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat Cell Biol. 2000, 2:E115-E119.
23. Gorbatyuk O.S., et al. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 2010, 18:1450-1457.
24. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro. 1 2009.
25. Greggio E., et al. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 2008, 283:16906-16914.
26. Greggio E., et al. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem. Biophys. Res. Commun. 2009, 389:449-454.
27. Han Y., et al. A microRNA embedded AAV alpha-synuclein gene silencing vector for dopaminergic neurons. Brain Res. 2011, 1386:15-24.
28. Hardy J., et al. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 2006, 60:389-398.
29. Hayashita-Kinoh H., et al. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 2006, 341:1088-1095.
30. Healy D.G., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008, 7:583-590.
31. Howland D.S., et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1604-1609.
32. Ibanez P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
33. Imai Y., et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 2001, 105:891-902.
34. Ito T., et al. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J. Biol. Chem. 2003, 278:29106-29114.
35. Ito G., et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 2007, 46:1380-1388.
36. Kamikawaji S., et al. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009, 48:10963-10975.
37. Khodr C.E., et al. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 2011, 1395:94-107.
38. Kinoshita A., et al. Differential localization of septins in the mouse brain. J. Comp. Neurol. 2000, 428:223-239.
39. Kirik D., et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
40. Kirik D., et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2884-2889.
41. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
42. Klein R.L., et al. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther. 2002, 13:605-612.
43. Klein R.L., et al. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol. Ther. 2006, 13:517-527.
44. Klein C.L., et al. Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment. J. Neurochem. 2009, 111:703-715.
45. Ko H.S., et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 2005, 25:7968-7978.
46. Ko H.S., et al. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J. Biol. Chem. 2006, 281:16193-16196.
47. Krenz A., et al. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors. J. Neurochem. 2009, 108:139-146.
48. Kruger R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
49. Kugler S., et al. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 2003, 10:337-347.
50. Lauwers E., et al. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol. 2003, 13:364-372.
51. Lee B.D., et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 2010, 16:998-1000.
52. Lesage S., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 2006, 354:422-423.
53. Li Y., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
54. Li X., et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
55. Lin X., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
56. Lo Bianco C., et al. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10813-10818.
57. Lo Bianco C., et al. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis. 2004, 17:283-289.
58. Lo Bianco C., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17510-17515.
59. Lo Bianco C., et al. Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J. Clin. Invest. 2008, 118:3087-3097.
60. Lucking C.B., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 2000, 342:1560-1567.
61. Maingay M., et al. Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. CNS Spectr. 2005, 10:235-244.
62. Marazziti D., et al. Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10189-10194.
63. Marazziti D., et al. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9846-9851.
64. Marx F.P., et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 2003, 12:1223-1231.
65. Mata I.F., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006, 29:286-293.
66. McFarland N.R., et al. Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J. Neurochem. 2009, 109:838-845.
67. Melrose H.L., et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis. 2010, 40:503-517.
68. Mena M.A., et al. On the pathogenesis and neuroprotective treatment of Parkinson disease: what have we learned from the genetic forms of this disease?. Curr. Med. Chem. 2008, 15:2305-2320.
69. Myhre R., et al. Genetic association study of synphilin-1 in idiopathic Parkinson's disease. BMC Med Genet. 2008, 9:19.
70. Nagano Y., et al. Siah-1 facilitates ubiquitination and degradation of synphilin-1. J. Biol. Chem. 2003, 278:51504-51514.
71. Ozelius L.J., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 2006, 354:424-425.
72. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
73. Palacino J.J., et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279:18614-18622.
74. Perez F.A., Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2174-2179.
75. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
76. Ribeiro C.S., et al. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J. Biol. Chem. 2002, 277:23927-23933.
77. Ross O.A., et al. Lrrk2 and Lewy body disease. Ann. Neurol. 2006, 59:388-393.
78. Sapru M.K., et al. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 2006, 198:382-390.
79. Sen S., et al. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem. 2009, 284:36346-36356.
80. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25:302-305.
81. Singleton A.B., et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
82. Smith W.W., et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
83. Spillantini M.G., et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6469-6473.
84. Sriram S.R., et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. Genet. 2005, 14:2571-2586.
85. St Martin J.L., et al. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J. Neurochem. 2007, 100:1449-1457.
86. Staropoli J.F., et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003, 37:735-749.
87. Takahashi H., et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994, 44:437-441.
88. Taymans J.M., Cookson M.R. Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010, 32:227-235.
89. Tong Y., et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14622-14627.
90. Um J.W., et al. Parkin ubiquitinates and promotes the degradation of RanBP2. J. Biol. Chem. 2006, 281:3595-3603.
91. Valente E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
92. Velayati A., et al. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010, 10:190-198.
93. Vilarino-Guell C., et al. VPS35 mutations in Parkinson disease. Am. J. Hum. Genet. 2011, 89:162-167.
94. Von Coelln R., et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10744-10749.
95. Wakabayashi K., et al. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 2000, 47:521-523.
96. West A.B., Maidment N.T. Genetics of parkin-linked disease. Hum. Genet. 2004, 114:327-336.
97. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16842-16847.
98. West A.B., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
99. Winkler S., et al. Alpha-synuclein and Parkinson disease susceptibility. Neurology 2007, 69:1745-1750.
100. Winner B., et al. In vivo demonstration that {alpha}-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
101. Yamada M., et al. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J. Neurochem. 2004, 91:451-461.
102. Yamada M., et al. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther. 2005, 16:262-270.
103. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
104. Zhang Y., et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13354-13359.
105. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
106. Zimprich A., et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. J. Hum. Genet. 2004, 74:11-19.
107. Zimprich A., et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011, 89:168-175.